MEDEA Biopharma’s Post

Only 10 new antibiotics or combinations were approved between 2017 and 2023, only two of which are defined as innovative by the World Health Organisation.                                                                                None are considered to constitute a new class of antibiotics.                                     Learn more about what the future antibiotic pipeline could look like in the new IFPMA report: https://shorturl.at/ivAlr #AMR #Antibiotics #ResearchAndDevelopment

The G7 Health Ministers’ Communiqué, October 10-11, 2024 reiterates support to R&D for novel antimicrobials, vaccines and diagnostics: "[G7 Health Ministers] ..will support funding for push incentives, including contributing to existing global pooled efforts to accelerate R&D of novel antimicrobials, vaccines and diagnostics and alternative therapeutics, through such efforts as CARB-X and Global Antibiotic R&D Partnership (GARDP). We also recognise the importance of tackling market failures of novel antimicrobial R&D, including through innovative market sustainable approaches. We reinforce our commitment to continue to expedite the urgent implementation of effective pull incentives in our regional and domestic markets and health systems, underpinned by the 2021 G7 Shared Principles for the Valuation of Antimicrobial Therapeutics. We support the work of the Global AMR R&D Hub facilitating evidence-based decision making in AMR R&D". 👉Read more here https://lnkd.in/dgq_5Wqk

Check out this #amr World Health Organization report!

As the UN General Assembly prepares for its important discussion on antimicrobial resistance (AMR) this week, this excellent overview by Ramanan Laxminarayan (founder and director of the One Health Trust) sheds light on the global challenges we face to preserve antibiotic effectiveness. He highlights that wealthier countries are struggling with infections that don’t respond to most antibiotics, making the need for new medicines urgent. Meanwhile, lower-income countries are battling a different issue—they need better access to existing antibiotics and more investment in preventing infections in the first place. Finding solutions that work for both, and that overcome AMR's lingering image problem, is key to tackling this growing crisis. https://lnkd.in/eZXm9kQM

New WHO report presents progress in G7 countries in tackling antibiotic pipeline crisis AMR is associated with more than a million deaths every year, however the R&D pipeline for new antibiotics is sparse, with lengthy and costly development and little innovation. The World Health Organization, in partnership with the Global AMR R&D Hub, has released a new report for #G7 Finance and Health Ministers detailing progress on incentivizing the development of new antibacterial treatments. It highlights the urgent need for innovative strategies to enhance research and preserve access to essential antibiotics. Read it here 👉 https://lnkd.in/dpG9Gbm8 Lesley Ogilvie #Cameron Tamarie Rocke Marcello Gemmato #AMR #FinancialIncentives The G20 & G7 Health and Development Partnership

🚨 𝑨 𝑮𝒍𝒐𝒃𝒂𝒍 𝑨𝒏𝒕𝒊𝒃𝒊𝒐𝒕𝒊𝒄 𝑪𝒓𝒊𝒔𝒊𝒔 𝒂𝒏𝒅 𝒕𝒉𝒆 𝑹𝒂𝒄𝒆 𝑨𝒈𝒂𝒊𝒏𝒔𝒕 𝑹𝒆𝒔𝒊𝒔𝒕𝒂𝒏𝒄𝒆 🚨 💊 The global pipeline for #newantibiotics is critically insufficient, struggling to keep pace with the escalating burden of #antibioticresistant infections worldwide. This issue is compounded by significant economic challenges and the situation is exacerbated by the growing crisis of antibiotic shortages and inequitable access to both existing and emerging treatments across many countries, regardless of income levels. 🌟Public and philanthropic funding has increasingly taken on the role of supporting antibiotic R&D, primarily through the creation of nonprofit public–private partnerships. Key initiatives include Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic R&D Partnership (GARDP). ❗❗The urgency of addressing #antimicrobialresistance (#AMR) is underscored by the staggering statistics: in 2019, drug-resistant infections were associated with 4.95 million deaths, including 1.27 million directly attributable deaths. If no action is taken, global life expectancy could decrease by 1.8 years over the next decade due to AMR. ⏰The burden of AMR is unevenly distributed, with the highest rates of drug-resistant infections occurring in regions with high antibiotic use, low vaccination coverage, poor sanitation, and inadequate access to clean water. 𝑼𝒍𝒕𝒊𝒎𝒂𝒕𝒆𝒍𝒚, 𝒈𝒍𝒐𝒃𝒂𝒍 𝒍𝒆𝒂𝒅𝒆𝒓𝒔 𝒂𝒏𝒅 𝒑𝒐𝒍𝒊𝒄𝒚𝒎𝒂𝒌𝒆𝒓𝒔 𝒎𝒖𝒔𝒕 𝒓𝒂𝒊𝒔𝒆 𝒕𝒉𝒆 𝒖𝒓𝒈𝒆𝒏𝒄𝒚 𝒂𝒏𝒅 𝒂𝒎𝒃𝒊𝒕𝒊𝒐𝒏 𝒐𝒇 𝒕𝒉𝒆𝒊𝒓 𝒄𝒐𝒎𝒎𝒊𝒕𝒎𝒆𝒏𝒕𝒔 𝒕𝒐 𝒇𝒖𝒍𝒍𝒚 𝒔𝒖𝒑𝒑𝒐𝒓𝒕 𝒕𝒉𝒆 𝒂𝒏𝒕𝒊𝒃𝒊𝒐𝒕𝒊𝒄 𝑹&𝑫 𝒆𝒄𝒐𝒔𝒚𝒔𝒕𝒆𝒎. 𝑻𝒉𝒊𝒔 𝒓𝒆𝒒𝒖𝒊𝒓𝒆𝒔 𝒏𝒐𝒕 𝒐𝒏𝒍𝒚 𝒇𝒊𝒏𝒂𝒏𝒄𝒊𝒂𝒍 𝒊𝒏𝒗𝒆𝒔𝒕𝒎𝒆𝒏𝒕 𝒃𝒖𝒕 𝒂𝒍𝒔𝒐 𝒕𝒉𝒆 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒐𝒇 𝒔𝒖𝒔𝒕𝒂𝒊𝒏𝒂𝒃𝒍𝒆 𝒎𝒐𝒅𝒆𝒍𝒔 𝒕𝒉𝒂𝒕 𝒅𝒆𝒍𝒊𝒏𝒌 𝑹&𝑫 𝒓𝒆𝒕𝒖𝒓𝒏𝒔 𝒇𝒓𝒐𝒎 𝒕𝒉𝒆 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒂𝒏𝒕𝒊𝒃𝒊𝒐𝒕𝒊𝒄𝒔 𝒔𝒐𝒍𝒅, 𝒕𝒉𝒆𝒓𝒆𝒃𝒚 𝒆𝒏𝒔𝒖𝒓𝒊𝒏𝒈 𝒕𝒉𝒂𝒕 𝒏𝒆𝒘 𝒂𝒏𝒕𝒊𝒃𝒊𝒐𝒕𝒊𝒄𝒔 𝒄𝒂𝒏 𝒃𝒆 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒆𝒅 𝒂𝒏𝒅 𝒎𝒂𝒅𝒆 𝒂𝒗𝒂𝒊𝒍𝒂𝒃𝒍𝒆 𝒕𝒐 𝒕𝒉𝒐𝒔𝒆 𝒘𝒉𝒐 𝒏𝒆𝒆𝒅 𝒕𝒉𝒆𝒎 𝒎𝒐𝒔𝒕. 𝑻𝒉𝒆 𝒇𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝒈𝒍𝒐𝒃𝒂𝒍 𝒉𝒆𝒂𝒍𝒕𝒉 𝒅𝒆𝒑𝒆𝒏𝒅𝒔 𝒐𝒏 𝒐𝒖𝒓 𝒄𝒐𝒍𝒍𝒆𝒄𝒕𝒊𝒗𝒆 𝒂𝒃𝒊𝒍𝒊𝒕𝒚 𝒕𝒐 𝒎𝒆𝒆𝒕 𝒕𝒉𝒆𝒔𝒆 𝒄𝒉𝒂𝒍𝒍𝒆𝒏𝒈𝒆𝒔 𝒉𝒆𝒂𝒅-𝒐𝒏, 𝒆𝒏𝒔𝒖𝒓𝒊𝒏𝒈 𝒕𝒉𝒂𝒕 𝒆𝒇𝒇𝒆𝒄𝒕𝒊𝒗𝒆 𝒂𝒏𝒕𝒊𝒃𝒊𝒐𝒕𝒊𝒄𝒔 𝒓𝒆𝒎𝒂𝒊𝒏 𝒂 𝒄𝒐𝒓𝒏𝒆𝒓𝒔𝒕𝒐𝒏𝒆 𝒐𝒇 𝒎𝒐𝒅𝒆𝒓𝒏 𝒎𝒆𝒅𝒊𝒄𝒊𝒏𝒆 𝒊𝒏 𝒕𝒉𝒆 𝒇𝒊𝒈𝒉𝒕 𝒂𝒈𝒂𝒊𝒏𝒔𝒕 𝒊𝒏𝒇𝒆𝒄𝒕𝒊𝒐𝒖𝒔 𝒅𝒊𝒔𝒆𝒂𝒔𝒆𝒔. https://lnkd.in/gMNySeUU #onehalth #antimiicrobialstewardship #AWARE #AMRACE Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Swissnex in India, Consulate General of Switzerland Bangalore Bioinnovation Centre Precision Health Platform AMR Insights the echo network

Please have a look at the publication in nature, which faces the world-wide emerging resistancy Problem of current antibiotics especially in hospitals: Here is the Link: https://lnkd.in/dDVKfGUf

Global antimicrobial resistance and antibiotic use in COVID-19 patients within health facilities: a systematic review and meta-analysis of aggregated participant data. 🌐 This study delves into the concerning issue of antimicrobial resistance and antibiotic use among COVID-19 patients in healthcare settings worldwide. 🦠 By conducting a systematic review and meta-analysis of aggregated participant data, the researchers aimed to shed light on the prevalence and patterns of antimicrobial resistance and antibiotic consumption in this population. 💊 The findings from this comprehensive analysis have significant implications for antimicrobial stewardship efforts and the optimization of treatment protocols for COVID-19 patients. #AntimicrobialResistance #COVID19 #MetaAnalysis 📊 https://lnkd.in/dtpmxRgV

Antimicrobial resistance (#AMR) is a growing global health crisis that could result in 39 million deaths by 2050, with infections increasingly resistant to medications. 🌍🦠 A recent study in The Lancet emphasizes the urgent need for innovation in antibiotics and improved healthcare access. Together, we can take action now to prevent this threat from escalating. Read the full article on CNN Health: https://lnkd.in/ekZNkQAY At AdjuTec, we are focused on developing novel solutions to combat antibiotic resistance 🦠. We’re excited to be launching our first clinical trial this fall 🍂, and there’s much more to come 🚀. #Superbugs #Healthcare #Innovation #ClinicalTrials #antimicrobialresistance #norway #pharma #biotech

This article in Science is intriguing. We know this is going to happen, yet we are doing very little about it. Is it because the timing isn’t right yet? Developing a new antibiotic today is complex and extremely costly, like any new drug, only to enter a market dominated by inexpensive generics that still work in most cases. Preparing for the future too early is rarely economically viable. The issue is similar in other areas of healthcare, such as pain management, where 'old' drugs, despite their flaws, hinder the development of new generations primarily due to cost, but also because we are so accustomed to using them—we've known them for a long time. The era of new antibiotics may not have arrived yet, and as Andreas Baumler suggests in his article, it may take a crisis before things change—but will we be able to act as swiftly as we did with COVID-19?